Parasitological efficacy of seasonal malaria chemoprevention in Nampula, northern Mozambique
View abstract on PubMed
Summary
This summary is machine-generated.Seasonal malaria chemoprevention (SMC) using SPAQ in Mozambique showed low efficacy against Plasmodium falciparum, with amodiaquine being the primary driver of any observed effect. Sulphadoxine and pyrimethamine did not significantly contribute to malaria prevention.
Area Of Science
- Malariology
- Pharmacometrics
- Infectious Disease Epidemiology
Background
- Seasonal malaria chemoprevention (SMC) with monthly sulphadoxine-pyrimethamine-amodiaquine (SPAQ) is now used in Central and East Africa.
- This study assessed SPAQ's effectiveness in a high-transmission area of northern Mozambique.
Purpose Of The Study
- To evaluate the pharmacometric assessment and efficacy of SPAQ in children.
- To determine the impact of SPAQ on malaria parasitaemia and identify factors influencing treatment outcomes.
Main Methods
- A pilot pharmacometric study was conducted within a larger SMC program in northern Mozambique.
- 460 children received SPAQ; blood samples were collected for malaria PCR, microscopy, and drug level analysis before and after treatment.
- Data were analyzed to assess parasitaemia prevalence, drug exposure, and treatment efficacy.
Main Results
- SPAQ reduced overall parasitaemia prevalence from 68% to 41%.
- Preventive efficacy was 97% for Plasmodium ovale but only 42% for Plasmodium falciparum.
- Amodiaquine exposure correlated with chemoprevention, while sulphadoxine and pyrimethamine did not show a significant effect.
Conclusions
- In Nampula, Mozambique, amodiaquine demonstrated low parasitological efficacy against malaria.
- Sulphadoxine and pyrimethamine provided no significant contribution to the chemoprevention observed in this study.

